Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Foundation for Angelman Syndrome Therapeutics

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LB-100

            Therapeutic Area: Genetic Disease Product Name: LB-100

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Lixte Biotechnology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 18, 2020

            Details:

            Collaboration will support the preclinical studies of the potential benefit of Lixte’s proprietary lead clinical compound, LB-100, in a mouse model of Angelman Syndrome (AS).